Patents Examined by Gary B. Nickol
  • Patent number: 10975158
    Abstract: In various embodiments chimeric moieties (constructs) are provided that show significant efficacy against cancers. In certain embodiments the constructs comprise a targeting moiety that specifically binds CD138 attached to an interferon or to a mutant interferon. In certain embodiments, the constructs comprise anti-CD138 antibody attached to an interferon alpha (IFN-?) or to a mutant interferon alpha.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: April 13, 2021
    Assignee: The Regents of the University of California
    Inventor: Sherie L. Morrison
  • Patent number: 10975153
    Abstract: Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: April 13, 2021
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Julie Hambleton, Emma Masteller, James Zanghi, Robert Sikorski, Hong Xiang
  • Patent number: 10975145
    Abstract: The present invention relates to an IL-1? binding antibody or a functional fragment thereof for use in preventing or reducing risk of experiencing a recurrent cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered of a qualifying CV event.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: April 13, 2021
    Assignee: Novartis AG
    Inventors: Tom Thuren, Andrew Zalewski, Michael Shetzline
  • Patent number: 10967012
    Abstract: Methods of formulating live biotherapeutics are disclosed in which a deficiency or excess of a specific bacterial strain in a person's microbiome is identified by comparing a gene-specific characterization of the person's microbiome against a comprehensive, non-redundant reference gene catalog, and the biotherapeutic is formulated by selecting bacteria to address the deficiency or excess. Embodiments include the formulation of live biotherapeutics for improving the health of a person's vaginal microbiome, i.e. using a vaginal reference gene catalog, and may be suitable for ameliorating, treating, or preventing a malignancy such as a cancer of the female genitourinary system.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: April 6, 2021
    Assignee: University of Maryland, Baltimore
    Inventors: Jacques Ravel, Michael France, Lindsay Rutt, Bing Ma
  • Patent number: 10968278
    Abstract: The present invention provides compositions and methods of treating and improving the symptoms of uveitis and/or macular edema using an antibody that specifically binds human interleukin-6 receptor (hIL-6R).
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: April 6, 2021
    Assignees: SANOFI BIOTECHNOLOGY, REGENERON PHARMACEUTICALS, INC.
    Inventors: Preethi Aavali Sridhara Sundaram, Ronald Buggage, Karen W. Chu, Valérie Corp dit Genti, Kristine A. Erickson, Dominique Mery-Mignard, Rafael Varona, Robert L. Vitti
  • Patent number: 10968274
    Abstract: Provided is an anti-INF-? antibody. Also provided are a composition comprising the antibody and a pharmaceutical application of the antibody in treating IFN-? mediated syndrome.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: April 6, 2021
    Assignee: Elixiron Immunotherapeutics (Hong Kong) Limited
    Inventors: Cheng-Lun Ku, Han-Po Shih, Chia-Hao Lin, Jing-Ya Ding, Jing-Yi Huang, Yi-Ting Kuo
  • Patent number: 10960071
    Abstract: Provided herein are cytoplasts, compositions comprising cytoplasts, methods of using cytoplasts, and methods of treating a subject, such as providing benefits to a healthy or unhealthy subject, or treating or diagnosing a disease or condition in a subject. In some embodiments, methods of treating a subject include: administering to the subject a therapeutically effective amount of a composition comprising a cytoplast. Also, provided herein are compositions (e.g., pharmaceutical compositions) that include a cytoplast. Also, provided herein are kits comprising instructions for using the compositions or methods.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: March 30, 2021
    Assignee: The Regents of the University of California
    Inventors: Richard Klemke, Huawei Wang
  • Patent number: 10960080
    Abstract: Disclosed herein are porcine interferon alpha variants (pIFN-?) comprising a synthetic amino acid at select locations in pIFN-? and a one or two amino acid insertion in the N-terminus after removal of the signal peptide. The pIFN-? variants can further be pegylated. Methods of making and administering these compounds to treat virus infections in pigs and formulations comprising the variants are also provided.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: March 30, 2021
    Assignees: Elanco US Inc., Ambrx, Inc.
    Inventors: Peter Connor Canning, Nickolas Knudsen, Lillian Skidmore
  • Patent number: 10953071
    Abstract: Pre-implantation factor (PIF) may be used to treat intracellular damage. Aspects of the invention are directed to a method of treating intracellular damage comprising administering PIF to a subject in need thereof. Some aspects may be directed to methods of increasing cytokine secretion in response to intracellular damage comprising administering PIF to a subject in need thereof. The intracellular damage may be a result of a disease such as Listeria monocytogenes infection, malaria, Lyme disease, cardiovascular disease, duodenal peptic ulcer, atherosclerosis, peritonitis or tuberculosis. In some aspects, a method of treating tuberculosis is disclosed, comprising administering PIF to a subject in need thereof. In some aspects, a method of treating atherosclerosis is disclosed, comprising administering PIF to a subject in need thereof. In some aspects, a method of treating peritonitis is disclosed, comprising administering PIF to a subject in need thereof.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: March 23, 2021
    Assignee: BIOINCEPT, LLC
    Inventor: Eytan R. Barnea
  • Patent number: 10953072
    Abstract: Methods of treating a hepatitis delta virus (HDV) infection in a human patient are provided. In some embodiments, the method comprising administering to the patient a therapeutically effective amount of interferon lambda for at least four weeks.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: March 23, 2021
    Assignee: EIGER BIOPHARMACEUTICALS, INC.
    Inventor: Eduardo Bruno Martins
  • Patent number: 10953090
    Abstract: The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: March 23, 2021
    Assignee: SNIPR Technologies Limited
    Inventors: Jasper Clube, Christian Grøndahl, Morten Sommer
  • Patent number: 10946070
    Abstract: This disclosure relates to a modified ?-helical bundle cytokine, with reduced activity via an ?-helical bundle cytokine receptor, wherein the ?-helical bundle cytokine is specifically delivered to target cells. Preferably, the ?-helical bundle cytokine is a mutant, more preferably it is a mutant interferon, with low affinity to the interferon receptor, wherein the mutant interferon is specifically delivered to target cells. The targeting is realized by fusion of the modified ?-helical bundle cytokine to a targeting moiety, preferably an antibody. This disclosure relates further to the use of such targeted modified ?-helical bundle cytokine to treat diseases. A preferred embodiment is the use of a targeted mutant interferon, to treat diseases, preferably viral diseases and tumors.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: March 16, 2021
    Assignees: VIB VZW, UNIVERSITEIT GENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER, UNIVERSITAT OSNABRUCK
    Inventors: Jan Tavernier, Gilles Uzé, Guillaume Cartron, Franciane Paul, Jacob Piehler
  • Patent number: 10947288
    Abstract: The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: March 16, 2021
    Assignees: VIB VZW, UNIVERSITEIT GENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER
    Inventors: Jan Tavernier, Lennart Zabeau, Gilles Uze, Franciane Paul, Yann Bordat, Genevieve Garcin
  • Patent number: 10941198
    Abstract: Provided are novel IFB-a binding molecules of human origin, particularly human-derived anti-IFN-? antibodies as well as IFN-? binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits, and methods for use in diagnosis and therapy are described.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: March 9, 2021
    Inventors: Syeda F. Y. Haque, Adrian Hayday, Kai Kisand, Kai Krohn, Annalisa Macagno, Steffen Meyer, Paert Peterson, Mike Rothe, Philip Vlaicu, Martin Woodward
  • Patent number: 10933119
    Abstract: The invention relates to aortopathy, and in particular, to compositions and methods for the diagnosis and treatment of aortopathy.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: March 2, 2021
    Assignee: University of Leicester
    Inventor: Toru Suzuki
  • Patent number: 10925929
    Abstract: The invention describes a method to modulate melanosome maturation process in melanocytes. Further, it describes a method to reversibly alter the process of pigmentation in the human epidermal skin. The method targets melanosome maturation and its transfer to keratinocytes, which are key processes involved in the pigmentation for its potential use in predictable and controlled regulation of pigmentation in human skin.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: February 23, 2021
    Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
    Inventors: Rajesh Sudhir Gokhale, Vivek Tirunelveli Natarajan, Parul Ganju
  • Patent number: 10927435
    Abstract: The present invention provides compositions and methods of treating and improving the symptoms of rheumatoid arthritis using an antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R) with a DMARD.
    Type: Grant
    Filed: October 10, 2012
    Date of Patent: February 23, 2021
    Assignees: SANOFI BIOTECHNOLOGY, REGENERON PHARMACEUTICALS, INC.
    Inventors: Xiaohong Huang, Martine Jasson, Vanessa Marks, Allen Radin
  • Patent number: 10925908
    Abstract: The subject invention provides materials and methods that effectively support innate immunity and/or disperse pathogenic biofilms using readily available, nontoxic, natural substances, while supporting restoration of normal microbiotic homeostasis. In one embodiment, the subject invention provides anti-biofilm compositions comprising one or more probiotic organisms, anti-microbial honey, and other ingredients such as prebiotic compounds, other hive products, green tea derivatives, other plant derivatives, and vitamin D3.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: February 23, 2021
    Assignee: QUORUM INNOVATIONS, LLC
    Inventors: Eva A. Berkes, Nicholas T. Monsul, Frederick T. Boehm
  • Patent number: 10918698
    Abstract: A novel and thermostable lyophilized pharmaceutical composition of Romiplostim (Fcpeptide fusion protein) along with buffer, bulking agent, stabilizer, and surfactant at pH range of 4.0-6.0.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: February 16, 2021
    Assignee: INTAS PHARMACEUTICALS LTD.
    Inventors: Himanshu Gadgil, Chandresh Chhatbar, Vijaykant Pandey
  • Patent number: 10919950
    Abstract: The present application relates to fusion proteins, chimeric antigen bearing cells expressing fusion proteins and compositions comprising chimeric antigen bearing cells expressing fusion proteins. The application further relates to methods of using the fusion proteins, cells and compositions for modulating an immune response.
    Type: Grant
    Filed: January 10, 2017
    Date of Patent: February 16, 2021
    Assignee: Seattle Children's Hospital
    Inventors: Michael C. Jensen, Adam Johnson